Purpose: Fentanyl transdermal system (FTS) is intended only for patients with prior opioid tolerance. The purpose of this study is to identify the proportion of new FTS users who had evidence of prior opioid tolerance, by dosage strength, in FDA's Sentinel System.
| INTRODUCTION
Fentanyl transdermal system (FTS, ie, fentanyl patch) is indicated for the management of pain in opioid-tolerant patients whose pain is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
FTS provides continuous treatment for 48 to 72 hours from a single application. FTS is an extended-release opioid analgesic formulation that is intended only for patients with prior opioid tolerance. The potential life-threatening or fatal respiratory depression associated with use of FTS in opioid-naïve patients is due to its relative potency, long duration of effect, and unpredictable individual-level variation in serum concentrations. 1 In July 2012, the US Food and Drug Administration (FDA) approved a Risk Evaluation and Mitigation Strategy (REMS) for extended-release or long-acting (ER/LA) opioid analgesics which requires their manufacturers to fund provider education on safe prescribing, though provider participation is not mandatory. 2 The intent of the REMS is to reduce serious adverse outcomes resulting from inappropriate prescribing, misuse, and abuse of these products and includes a requirement that manufacturers make prescriber training on appropriate prescribing of these medications available-including, but not limited to, training on opioid tolerance. The REMS-affiliated provider training began in March 2013.
A metric to identify prior opioid tolerance in patients prescribed select ER/LA opioid analgesics requiring opioid tolerance was developed and applied to the US Medicare population. 3 We have extended that work, applying the metric in a different population and including additional products. 4 In that study, we assessed evidence of prior opioid tolerance among new users of FTS across all dosage strengths. We found that only 40% of all FTS episodes were preceded by evidence of opioid tolerance as defined by the product label. After the initial results, we hypothesized that prescribers may more commonly prescribe the lowest dosage fentanyl patch to opioid non-tolerant patients because of a possible lack of awareness that all fentanyl patch dosages require opioid tolerance. Here, we report on the proportion of new users of FTS with evidence of prior opioid tolerance, by different definitions of tolerance, stratified by dosage strength and other covariates.
| METHODS
The US FDA's Sentinel System is an active surveillance system that uses pre-existing electronic health care data, primarily commercial health plans, to monitor the safety of regulated medical products. The primary definition of opioid tolerance, as specified in the product labeling, is defined as ≥30-mg oxycodone equivalents per day for 7 consecutive days immediately prior to the new opioid-tolerant-only dose index date. We also examined results for three less stringent definitions of tolerance: ≥30-mg oxycodone equivalents per day in any 7 days of the 30 days prior to index (secondary); any dose for 7 consecutive days immediately prior to index (tertiary); or any dose for any 7 days in the 30 days prior to index (quaternary).
How we estimated daily dosages and calculated tolerance was previously described. 4 Prescription claims provide the strength, quantity dispensed, and the days supplied. To calculate an estimated daily opioid dosage for each opioid dispensing, we assumed the quantity was distributed equally over the days supplied. We summed the estimated dosage of any overlapping dispensings on each day. More than one dispensing on the same day were summed together, but only the manufacturer-specific strengths are reported here (12, 25, 50, 75, and 100 mcg/hr). We used standard conversion tables to calculate oxycodone equivalent dosages for each dispensing (see Appendix Table 1 in   Larochelle et al   4   ) . [6] [7] [8] We identified the number of FTS episodes overall and by age and year. We calculated the proportion of episodes with evidence of prior opioid tolerance by tolerance definition and dosage strength. Our results suggest that providers may not recognize that at all dosages, FTS requires established opioid tolerance prior to use. These baseline period results demonstrate the need to understand the knowledge gaps among prescribing providers of FTS specifically, and ER/LA opioid analgesics in general. Provider training/education may address these knowledge gaps. In September 2017, the FDA announced the expansion of the REMS to include immediate-release opioids intended for outpatient use, and along with that expansion, the provider training will be expanded in scope as well to address pain management more broadly, and the appropriate use of opioids within that broader context. Understanding appropriate patient selection (eg, opioid-tolerant patients in the case of FTS) will be emphasized within the revised "blueprint" for the provider training.
In addition to validation of the metric, we recommend that future research focus on assessing the extent to which use of ER/LA opioid analgesics requiring opioid tolerance by non-opioid-tolerant individuals is associated with increased risk of opioid-related harms.
ETHICS STATEMENT
This analysis was conducted under the Sentinel program as a public health activity; thus, this work is not research, and IRB approval is not required.
